Page last updated: 2024-12-06

thiazole-4-carboxamide adenine dinucleotide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thiazole-4-carboxamide adenine dinucleotide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73680
CHEMBL ID394276
MeSH IDM0115019

Synonyms (12)

Synonym
adenosine 5'-(trihydrogen diphosphate), p'.fwdarw.5'-ester with2-.beta.-d-ribofuranosyl-4-thiazolecarboxamide
adenosine 5'-(trihydrogen diphosphate), 5'-5'-ester with 2-beta-d-ribofuranosyl-4-thiazolecarboxamide
thiazole-4-carboxamide adenine dinucleotide
tcad
nsc 358285
[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2r,3s,4r,5r)-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid
bdbm19253
chembl394276 ,
tiazofurin adenine dinucleotide (tad)
tiazofurin adenine dinucleotide
[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2r,3s,4r,5r)-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]hydrogen phosphate
[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)Ki0.10670.00600.12620.2600AID1797841; AID303352; AID304372
Inosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)Ki0.10670.03300.16540.3300AID1797840; AID303351; AID304371
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
circadian rhythmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
lymphocyte proliferationInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cellular response to interleukin-4Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
'de novo' XMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
nucleotide bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
protein bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleotide bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
nucleic acid bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
extracellular regionInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
peroxisomal membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular exosomeInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular regionInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
azurophil granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID303352Inhibition of human IMPDH type 22007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
AID427151Inhibition of human IMPDH2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Selective inhibition of nicotinamide adenine dinucleotide kinases by dinucleoside disulfide mimics of nicotinamide adenine dinucleotide analogues.
AID304372Inhibition of human IMPDH 22007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
AID304371Inhibition of human IMPDH 12007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
AID342524Inhibition of IMP dehydrogenase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase.
AID303351Inhibition of human IMPDH type 12007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
AID303356Antiproliferative activity against human K562 cells after 72 hrs2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
AID427147Inhibition of horse liver alcohol dehydrogenase2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Selective inhibition of nicotinamide adenine dinucleotide kinases by dinucleoside disulfide mimics of nicotinamide adenine dinucleotide analogues.
AID304373Inhibition of HDAC2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
AID1797840IMPDH Type 1 Enzyme Assay from Article 10.1021/jm070568j: \\Probing Binding Requirements of Type I and Type II Isoforms of Inosine Monophosphate Dehydrogenase with Adenine-Modified Nicotinamide Adenine Dinucleotide Analogues.\\2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
AID1797841IMPDH Type 2 Enzyme Assay from Article 10.1021/jm070568j: \\Probing Binding Requirements of Type I and Type II Isoforms of Inosine Monophosphate Dehydrogenase with Adenine-Modified Nicotinamide Adenine Dinucleotide Analogues.\\2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (37.93)18.7374
1990's12 (41.38)18.2507
2000's6 (20.69)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.81 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.33%)4.05%
Observational0 (0.00%)0.25%
Other28 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients [NCT00867139]Phase 1/Phase 27 participants (Actual)Interventional2009-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00867139 (12) [back to overview]Days on Supplemental Oxygen
NCT00867139 (12) [back to overview]Duration of Hospitalization
NCT00867139 (12) [back to overview]Duration of Symptoms
NCT00867139 (12) [back to overview]Frequency of Confirmed Pneumonia
NCT00867139 (12) [back to overview]Number of Deaths
NCT00867139 (12) [back to overview]Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption
NCT00867139 (12) [back to overview]Number of Participants With ICU Admissions
NCT00867139 (12) [back to overview]Number of Participants With Intubations
NCT00867139 (12) [back to overview]Number of Participants With Viral Load Decrease as a Function of Time
NCT00867139 (12) [back to overview]Number of Participants With Viral Resistance as a Function of Drug Exposure
NCT00867139 (12) [back to overview]Pharmacokinetics (AUC0-last) of TCAD
NCT00867139 (12) [back to overview]Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1

Days on Supplemental Oxygen

(NCT00867139)
Timeframe: 58 days

Interventiondays (Mean)
TCAD2
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD0

[back to top]

Duration of Hospitalization

(NCT00867139)
Timeframe: from baseline up to 58 days

Interventiondays (Mean)
TCAD6
Neuraminidase Inihibitor Monotherapy6
Open-labeled TCAD1

[back to top]

Duration of Symptoms

"Calculated as the number of days (mean) any persistent symptom lasted per patient as listed below.~overall health, short of breath, chills, cough, diarrhea, ear pain, fatigue, fever, headache, hoarseness, muscle ache, phlegm, runny nose, sinus congestion, sneezing, sore throat, watery eyes, wheezing" (NCT00867139)
Timeframe: from baseline up to 28 days

Interventiondays (Mean)
TCAD4.5
Neuraminidase Inhibitor Monotherapy1
Open-label TCAD4.7

[back to top]

Frequency of Confirmed Pneumonia

(NCT00867139)
Timeframe: 58 days

Interventionparticipants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD1

[back to top]

Number of Deaths

(NCT00867139)
Timeframe: 58 days

Interventionparticipants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD0

[back to top]

Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption

"Abnormal lab data or newly appeared symptoms & signs were considered as AEs.~Examined lab data:~Blood cell count (WBC, differential count, Red Blood Cell (RBC), Hemoglobin, Hematocrit, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin Concentration (MCHC), platelets), Chemistry (Cl, bicarbonate (HCO3), K, Na), Renal function test (BUN, Creatinine, Creatinine clearance), Liver function test (AST, Alanine aminotransferase(ALT), T.Bil, gamma-glutamyltransferase)" (NCT00867139)
Timeframe: 30 days after the final dose of study drug

Interventionnumber of participants with AEs (Number)
TCAD1
Neuraminidase Inihibitor Monotherapy1
Open-labeled TCAD1

[back to top]

Number of Participants With ICU Admissions

The number of participants with ICU admissions was evaluated. (NCT00867139)
Timeframe: baseline and up to 58 days

Interventionparticipants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD1

[back to top]

Number of Participants With Intubations

(NCT00867139)
Timeframe: 58 days

Interventionparticipants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy0
Open-labeled TCAD1

[back to top]

Number of Participants With Viral Load Decrease as a Function of Time

Viral loads were measured by quantitative Polymerase Chain Reaction (PCR) on day 1, 3, 5, 7, 9, 15, 20 and 28, if applicable. (NCT00867139)
Timeframe: baseline and 28 days

Interventionnumber of participants (Number)
Neuraminidase Inhibitor Monotherapy0
Open-label TCAD2

[back to top]

Number of Participants With Viral Resistance as a Function of Drug Exposure

Viral resistance was assessed within 28 days after drug administration by detecting resistance-conferring mutation genes and compared to the value at baseline. (NCT00867139)
Timeframe: 28 days

InterventionNumber of participants (Number)
TCAD0
Neuraminidase Inihibitor Monotherapy1
Open-labeled TCAD0

[back to top]

Pharmacokinetics (AUC0-last) of TCAD

Only 5 patients had partial pharmacokinetic (PK) data available. Plasma concentration of oseltamivir was measured at several time points in one patient receiving neuraminidase inhibitor monotherapy. Plasma concentration of oseltamivir, amantadine, and ribavirin were measured at several time points in four patients receiving TCAD therapy. Area under the time-concentration curve up to the last measured time point (AUC0-last) was calculated from the plasma concentration-time profiles by non-compartmental analysis. (NCT00867139)
Timeframe: 5 days

Interventionng*hr/mL (Mean)
TCAD304
Neuraminidase Inhibitor Monotherapy1497
Open-lable TCAD2487

[back to top]

Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1

(NCT00867139)
Timeframe: 10 days

,
Interventionparticipants (Number)
Day 5 +/-1Day 10 +/- 1
Neuraminidase Inihibitor Monotherapy00
Open-labeled TCAD01

[back to top]